Faroe Islands vs Switzerland: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Faroe Islands
0.0%
in 2024
Switzerland
0.0%
in 2024
Faroe Islands rank
167th
Switzerland rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Faroe Islands
- Switzerland
How they compare
Faroe Islands currently reports 0.0% against 0.0% in Switzerland, a difference of 0.0%.
The two have swapped places 2 times across 10 shared years of data; in 2015 it was Switzerland ahead.
Faroe Islands ranks 167th and Switzerland ranks 167th of 246 countries.
Faroe Islands has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Faroe Islands | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.0% | 0.1% | Faroe Islands |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Faroe Islands or Switzerland?
- Faroe Islands, at 0.0% against 0.0% in Switzerland as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Faroe Islands and Switzerland?
- 0.0%, with Faroe Islands ahead.
- How many years of comparable data are there for Faroe Islands and Switzerland?
- 10 years are reported by both, from 2015 to 2024.
- How do Faroe Islands and Switzerland rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Faroe Islands ranks 167th and Switzerland ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.